SETD2 loss is associated with aggressive forms of renal, gastric, colon, and pancreatic cancers 69, and it has been implicated in the development of aggressive gastrointestinal mesenchymal tumors 70. This evidence concerns the gene SETD2 and familial pancreatic carcinoma.